Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Forgoes Cost Cuts, Predicting Stent/ICD Market Recovery

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific will maintain current cost structures in its drug-eluting stent and cardiac rhythm management businesses in the near term, anticipating both markets will soon recover from a 2006 slump
Advertisement

Related Content

Recent Resurgence Of Bare-Metal Stents Will Be Short-Lived, Experts Say
Boston Scientific Pursues Cost Cutting, Asset Sales
Boston Scientific Initiates Another ICD Battery Depletion Recall
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
Boston Scientific Weighs Endosurgery IPO, Other Asset Sales To Repay Debt
St. Jude Expects ICD Investments To Bear Fruit In 2007
Boston Scientific Expects To Be Ready For FDA Inspections By Summer
Boston Scientific Expects To Be Ready For FDA Inspections By Summer
Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data
Guidant’s Problems Go Beyond Bad Communication – Boston Scientific CEO
Advertisement
UsernamePublicRestriction

Register

MT024475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel